# Ahammune Biosciences Pvt.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ahammune-biosciences-pvt

- Industry: Pharmaceuticals
- Headquarters: Pune, India
- Website: www.ahammune.com
- Total disclosed funding: $6.4M
- Latest round: Series A (Sep 28, 2024)
- Investors on record: 9

## About

Ahammune Biosciences Pvt. Ltd. is an Indian biotechnology firm focused on developing innovative therapeutic solutions for skin health, particularly in treating dermatological conditions such as vitiligo.Founded in 2016 and headquartered in Pune, India, Ahammune Biosciences specializes in creating treatments for skin diseases. The company was co-founded by Krishnamurthy Natarajan and Parul Ganju, who previously founded other ventures. Ahammune has raised a total of USD 5.00 mn through three deals, with the most recent being a Series A funding round in September 2024 led by Pi Ventures, along with participation from multiple investors including Ideaspring Capital and the Indian Angel Network.Ahammune Biosciences specializes in innovative therapeutic solutions aimed at restoring skin health, focusing on treating skin conditions such as vitiligo. Their core offerings include proprietary small molecules designed to target deregulated cellular pathways linked to skin diseases, specifically affecting melanocytes. These products cater to healthcare providers and patients globally, particularly in North America, Europe, and select Asian regions, including healthcare institutions and dermatology clinics treating chronic skin conditions.In 2023, Ahammune Biosciences reported no revenue, with an EBITDA of USD -56,719.90. The company generates revenue through direct sales of its therapeutic products to healthcare providers and dermatology clinics, primarily from its offerings targeting vitiligo and other skin conditions.Following its most recent funding round on September 25, 2024, where Ahammune Biosciences raised USD 5.00 mn in Series A funding, the company plans to use this capital to support the development and Phase II clinical trial of its vitiligo drug. The firm is targeting expansion into new markets, including regions in Europe and Asia, by the end of 2025, aiming to enhance its product offerings and availability.

## Funding rounds

- Series A, Sep 28, 2024, $4.6M — Kotak Alternate Asset Managers, Indian Angel Network, Ideaspring Capital, pi Ventures, InfoEdge Ventures, Colossa Ventures, Capital 2B, Legacy Assets LLP, Unicornus Maximus
- Seed, Feb 16, 2021, $1.8M — Kotak Alternate Asset Managers, Indian Angel Network, Ideaspring Capital, Legacy Assets LLP

## Investors

- Kotak Alternate Asset Managers (https://capitalatlas.ai/funds/kotak-alternate-asset-managers) — Seed, Series A
- Indian Angel Network (https://capitalatlas.ai/funds/indian-angel-network) — Seed, Series A
- Ideaspring Capital (https://capitalatlas.ai/funds/ideaspring-capital) — Seed, Series A
- Legacy Assets LLP — Seed, Series A
- pi Ventures (https://capitalatlas.ai/funds/pi-ventures) — Series A
- InfoEdge Ventures (https://capitalatlas.ai/funds/infoedge-ventures) — Series A
- Colossa Ventures (https://capitalatlas.ai/funds/colossa-ventures) — Series A
- Capital 2B (https://capitalatlas.ai/funds/capital-2b) — Series A
- Unicornus Maximus — Series A